BR112015029309A2 - derivados de polimixina e seu uso em terapia de combinação junto com antibióticos diferentes - Google Patents

derivados de polimixina e seu uso em terapia de combinação junto com antibióticos diferentes

Info

Publication number
BR112015029309A2
BR112015029309A2 BR112015029309A BR112015029309A BR112015029309A2 BR 112015029309 A2 BR112015029309 A2 BR 112015029309A2 BR 112015029309 A BR112015029309 A BR 112015029309A BR 112015029309 A BR112015029309 A BR 112015029309A BR 112015029309 A2 BR112015029309 A2 BR 112015029309A2
Authority
BR
Brazil
Prior art keywords
combination therapy
different antibiotics
polymyxin derivatives
polymyxin
derivatives
Prior art date
Application number
BR112015029309A
Other languages
English (en)
Inventor
Duperchy Esther
Dawson Michael
Simonovic Mona
Brown Pamela
Boakes Steven
Original Assignee
New Pharma Licence Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201309248A external-priority patent/GB201309248D0/en
Priority claimed from GB201404301A external-priority patent/GB201404301D0/en
Application filed by New Pharma Licence Holdings Ltd filed Critical New Pharma Licence Holdings Ltd
Publication of BR112015029309A2 publication Critical patent/BR112015029309A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

resumo “derivados de polimixina e seu uso em terapia de combinação junto com antibióticos diferentes” são descritos compostos da fórmula (i) para uso em tratamento de combina-ção com um segundo agente ativo, tal como rifampicina, por exemplo, para o trata-mento de uma infecção microbiana. o composto da fórmula (i) é um composto de polimixina: em que os grupos -a-, -r1, -r2, -r3, -r4, -r5, -r6, -r7, -r8 e -x- são descritos em detalhes dentro da descrição.
BR112015029309A 2013-05-22 2014-05-21 derivados de polimixina e seu uso em terapia de combinação junto com antibióticos diferentes BR112015029309A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201309248A GB201309248D0 (en) 2013-05-22 2013-05-22 Compounds and combinations
GB201404301A GB201404301D0 (en) 2014-03-11 2014-03-11 Compounds and combinations
PCT/GB2014/051547 WO2014188178A1 (en) 2013-05-22 2014-05-21 Polymyxin derivatives and their use in combination therapy together with different antibiotics

Publications (1)

Publication Number Publication Date
BR112015029309A2 true BR112015029309A2 (pt) 2017-07-25

Family

ID=50829204

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015029309A BR112015029309A2 (pt) 2013-05-22 2014-05-21 derivados de polimixina e seu uso em terapia de combinação junto com antibióticos diferentes

Country Status (20)

Country Link
US (1) US10407467B2 (pt)
EP (1) EP2999711B1 (pt)
JP (1) JP6643758B2 (pt)
KR (1) KR102354902B1 (pt)
CN (1) CN105308065B (pt)
BR (1) BR112015029309A2 (pt)
CA (1) CA2939061C (pt)
DK (1) DK2999711T3 (pt)
ES (1) ES2923762T3 (pt)
HK (1) HK1221474A1 (pt)
HR (1) HRP20220898T1 (pt)
HU (1) HUE059544T2 (pt)
LT (1) LT2999711T (pt)
PL (1) PL2999711T3 (pt)
PT (1) PT2999711T (pt)
RS (1) RS63484B1 (pt)
RU (1) RU2730012C2 (pt)
SI (1) SI2999711T1 (pt)
TW (1) TWI665218B (pt)
WO (1) WO2014188178A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012338571B2 (en) 2011-11-18 2016-06-16 New Pharma Licence Holdings Limited Polymyxin derivatives
DK2999711T3 (da) 2013-05-22 2022-07-18 Spero Therapeutics Inc Polymyxin-derivater og deres anvendelse i kombinationsterapi sammen med forskellige antibiotika
WO2015031579A2 (en) * 2013-08-28 2015-03-05 The Medicines Company Methods for treating bacterial infections using oritavancin and polymyxins
RS63138B1 (sr) * 2014-03-11 2022-05-31 Spero Therapeutics Inc Derivati polimiksina i njihova upotreba u kombinovanoj terapiji zajedno sa različitim antibioticima
WO2016100578A2 (en) 2014-12-16 2016-06-23 Micurx Pharmaceuticals, Inc. Antimicrobial polymyxins for treatment of bacterial infections
FI126143B (en) 2015-01-15 2016-07-15 Northern Antibiotics Oy Polymyxine derivative and its uses
US9763996B2 (en) 2015-01-16 2017-09-19 Northern Antibiotics, Ltd. Polymyxin derivative and uses thereof
KR101790296B1 (ko) * 2015-03-26 2017-10-26 한국생명공학연구원 네트롭신을 유효성분으로 포함하는 그람음성 세균에 대한 폴리믹신의 항균 활성을 증가시키는 조성물
WO2016166103A1 (en) * 2015-04-13 2016-10-20 Xellia Pharmaceuticals Aps Polymyxin derivatives
JP7367950B2 (ja) * 2015-09-29 2023-10-24 モナッシュ ユニバーシティ 抗菌性ポリミキシン誘導体化合物
WO2018035183A1 (en) * 2016-08-16 2018-02-22 University Of Rochester Pharmaceutical composition containing polymyxin b/trimethoprim based therapeutics
CN106631902A (zh) * 2016-09-23 2017-05-10 上海步越化工科技有限公司 一种特拉万星侧链癸基(2‑氧代乙基)氨基甲酸9h‑芴‑9‑甲基酯的制备方法
US11191773B2 (en) 2017-07-17 2021-12-07 President And Fellows Of Harvard College Methods of treatment for bacterial infections
WO2019085926A1 (zh) * 2017-10-31 2019-05-09 上海医药工业研究院 多黏菌素类似物及其制备方法
WO2019084628A1 (en) 2017-11-02 2019-05-09 The University Of Queensland Peptide antibiotics
US11713335B2 (en) 2018-03-12 2023-08-01 President And Fellows Of Harvard College Aminocoumarin compounds and methods of their use
MX2020013811A (es) 2018-06-25 2021-03-09 Spero Therapeutics Inc Compuestos.
CN111690040A (zh) * 2019-03-12 2020-09-22 上海来益生物药物研究开发中心有限责任公司 多粘菌素衍生物、其制备方法和应用
CN110179967A (zh) * 2019-05-28 2019-08-30 中国医药集团总公司四川抗菌素工业研究所 多粘菌素母核和一种抗生素的组合物及其应用
US20230141981A1 (en) 2020-01-21 2023-05-11 Shanghai Micurx Pharmaceuticals Co., Ltd Novel compounds and composition for targeted therapy of kidney-associated cancers
US20230233590A1 (en) * 2020-07-02 2023-07-27 Purdue Research Foundation Inhalation formulations of antimicrobial compounds
WO2022098950A1 (en) 2020-11-06 2022-05-12 Spero Therapeutics, Inc. Compounds
EP4289272A4 (en) * 2021-02-02 2024-07-17 Korea Res Inst Bioscience & Biotechnology ANTIMICROBIAL ADJUVANT CONTAINING A COMPOUND DERIVED FROM BIPHENYL AS ACTIVE INGREDIENT, AND USES THEREOF
KR20240035513A (ko) 2021-07-09 2024-03-15 알리고스 테라퓨틱스 인코포레이티드 항바이러스 화합물
WO2024003042A1 (en) 2022-06-28 2024-01-04 Breakthrough Biotech Drift Aps Novel combinations of sesquiterpene alcohols, polymyxins and nisin compounds as antimicobial and/or antifungal compounds
WO2024105689A1 (en) * 2022-11-14 2024-05-23 Cipla Limited Novel ophthalmic composition

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
AU7753787A (en) 1986-08-06 1988-02-24 Jean-Luc Fauchere Production of covalent-linked conjugates from an antibiotic and a non-toxic derivative of polymyxine b
US20010021697A1 (en) 1987-09-14 2001-09-13 Henning Lowenstein Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinageous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
TW274552B (pt) 1992-05-26 1996-04-21 Hoechst Ag
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
JP4583559B2 (ja) * 2000-07-24 2010-11-17 栄研化学株式会社 Ｍｒｓａスクリーニング用培地
CN1886128A (zh) 2003-09-30 2006-12-27 柯西有限公司 用于治疗灼伤的组合物及方法
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
WO2008001773A1 (en) 2006-06-27 2008-01-03 Toyo Tire & Rubber Co., Ltd. Run flat tire
DK2057185T3 (en) * 2006-08-11 2016-06-13 Northern Antibiotics Oy POLYMYXIN DERIVATIVES AND APPLICATIONS THEREOF
US8193148B2 (en) 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
FI20085469A0 (fi) 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
US8329645B2 (en) 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
ES2334547B1 (es) 2008-09-10 2010-12-03 Universidad De Barcelona Compuestos peptidicos antibacterianos.
WO2010075416A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
JP5493387B2 (ja) * 2009-02-25 2014-05-14 国立大学法人 東京大学 選択培地の製造方法及びその利用
CN101851270A (zh) 2009-04-03 2010-10-06 梁浩 一种多粘菌素衍生物及其制备方法
WO2010130007A1 (en) 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012051663A1 (en) 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
US9226786B2 (en) * 2011-03-22 2016-01-05 Lexion Medical Llc Medical devices for clearing a surgical site
WO2012168820A1 (en) 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
AU2012338571B2 (en) * 2011-11-18 2016-06-16 New Pharma Licence Holdings Limited Polymyxin derivatives
DK2999711T3 (da) 2013-05-22 2022-07-18 Spero Therapeutics Inc Polymyxin-derivater og deres anvendelse i kombinationsterapi sammen med forskellige antibiotika
USRE48335E1 (en) 2014-04-01 2020-12-01 Monash University Polymyxin derivatives as antimicrobial compounds

Also Published As

Publication number Publication date
KR20160009041A (ko) 2016-01-25
ES2923762T3 (es) 2022-09-30
HUE059544T2 (hu) 2022-11-28
US10407467B2 (en) 2019-09-10
WO2014188178A9 (en) 2015-01-08
DK2999711T3 (da) 2022-07-18
TWI665218B (zh) 2019-07-11
US20160222061A1 (en) 2016-08-04
RS63484B1 (sr) 2022-09-30
CN105308065A (zh) 2016-02-03
EP2999711B1 (en) 2022-06-29
RU2730012C2 (ru) 2020-08-14
CA2939061C (en) 2023-10-24
JP6643758B2 (ja) 2020-02-12
JP2016527186A (ja) 2016-09-08
SI2999711T1 (sl) 2022-10-28
WO2014188178A1 (en) 2014-11-27
EP2999711A1 (en) 2016-03-30
CA2939061A1 (en) 2014-11-27
PT2999711T (pt) 2022-07-29
HRP20220898T1 (hr) 2022-10-14
TW201444876A (zh) 2014-12-01
CN105308065B (zh) 2021-10-15
LT2999711T (lt) 2022-09-12
HK1221474A1 (zh) 2017-06-02
PL2999711T3 (pl) 2022-09-26
KR102354902B1 (ko) 2022-01-24
RU2015148032A (ru) 2017-06-27

Similar Documents

Publication Publication Date Title
BR112015029309A2 (pt) derivados de polimixina e seu uso em terapia de combinação junto com antibióticos diferentes
CO2018012894A2 (es) Derivados de pirazol como inhibidores de calicreína plasmática
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
BR112015027704A2 (pt) Composto, uso do mesmo e composição farmacêutica antibacteriana
CO2017001035A2 (es) “2-(morfolin-4-il)-1,7-naftiridinas sustituidas, composiciones y combinaciones farmacéuticas que las comprenden, y compuestos intermediarios
UY37201A (es) Nuevos derivados de pirazolopirimidina
BR112018076169A2 (pt) derivados azabenzimidazol como inibidores de pi3k beta
CL2021001042A1 (es) Nuevos compuestos antihelmínticos
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112015016001A2 (pt) compostos, composições farmacêuticas e respectivos usos e método para tratar ou prevenir infecção bacteriana
AR108021A1 (es) Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3
BR112017004153A2 (pt) métodos para tratamento de infecções por protozoários
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
MX2016011682A (es) Derivados de polimixina y su uso en terapia de combinacion junto con diferentes antibioticos.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112017006113A2 (pt) combinações sinérgicas de auristatina
BR112015022092A8 (pt) derivado de di-hidropiridazina-3,5-diona, seu uso e agente preventivo e/ou terapêutico comprendendo o mesmo
BR112015026259A2 (pt) combinações de ligantes de adrenoceptor alfa-2 e receptor sigma
UY32131A (es) Compuestos de anillo fusionado y uso de los mismos
BR112016005417A8 (pt) "compostos derivados de desoxinojirimicina, composição farmacêutica e seus usos"
BR112013024974A2 (pt) composto, composição farmacêutica, método para o tratamento de infecções virais, e, processo para preparar um composto
CL2015001943A1 (es) Derivados de bencilamina
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
BR112015014737A2 (pt) compostos spiroisoxazolina tendo uma atividade potencializando a atividade de um antibiótico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: SPERO THERAPEUTICS, INC. (US)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]